During the past 3 years, the average EBITDA Per Share Growth Rate was 46.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 57.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Iterum Therapeutics was 68.60% per year. The lowest was -58.50% per year. And the median was 48.50% per year.
Competitive Comparison of Iterum Therapeutics's 5-Year EBITDA Growth Rate
For the Biotechnology subindustry, Iterum Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's 5-Year EBITDA Growth Rate falls into.
Iterum Therapeutics 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Iterum Therapeutics (NAS:ITRM) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Iterum Therapeutics 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Iterum Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ITRM has been successfully added to your